OpenBit ResearchOpenBit
中文

What's driving Cogent Biosciences (COGT)

Compiled from the engine's research, source claims and public filings in this dossier. Each has its own data date, listed below.

Research summary

Bezuclastinib Advances Through FDA Review in Advanced Systemic Mastocytosis

Why it matters now

Approval or failure of bezuclastinib would directly affect COGT's potential product revenue; the regulatory outcome also affects valuation.

Next checkpoint

COGT earnings (expected 2026-11-06)

This checkpoint sits on a shared driver. The engine does not explain how it carries over to COGT, so treat it as context, not a verified checkpoint for this company.

What would break the thesis

FDA review rejects the application or determines that the submitted clinical evidence does not support approval.

Research drivers

  • Bezuclastinib Advances Through FDA Review in Advanced Systemic Mastocytosis

    Bullish · Cooling · Updated

    The accepted NDA and positive pivotal-trial evidence support continued regulatory progress for bezuclastinib in advanced systemic mastocytosis.

Source claims

Source labels are as recorded in our data. The dossier does not include links to the originals, so these are not verified quotations.

  • The bezuclastinib NDA is supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with advanced systemic mastocytosis.

    Source: GlobeNewsWire · Event date on record:

  • Cogent Biosciences announced that the FDA accepted its New Drug Application for bezuclastinib in patients with advanced systemic mastocytosis.

    Source: GlobeNewsWire · Event date on record:

Related sectors

Biotech

Filed holders

This dossier has no filed holders to show. That does not mean no institution holds it.